-
SpeichernDas Eingabefeld wird
gespeichert wenn Sie das Feld
verlassen oder hier klicken.↓USDISIN US98401F1057-
XencorBörse Börse FrankfurtEURSymbol XE9
-
XencorBörse Börse BerlinEURSymbol XE9
-
XencorBörse Börse MünchenEURSymbol XE9
-
XENCOR INCBörse Börse StuttgartEURSymbol XE9
-
XENCOR INCBörse Tradegate System der Deutsche Börse AG (60%)EURSymbol XE9
-
XENCOR INCBörse Quotrix System der Börse DüsseldorfEURSymbol XE9
-
XENCOR INCBörse Börse DüsseldorfEURSymbol XE9
-
XENCOR INCBörse Gettex System der Börse MünchenEURSymbol XE9
-
XencorBörse Börse Stuttgart
-
ISIN US98401F1057 WKN: A1W96LUSDSymbol XNCR
-
USDISIN US98401F1057
-
ISIN US98401F1057
WKN A1W96L
Symbol XNCR
Währung
USD
Firmenname
Xencor, Inc
Marktkapitalisierung
2.294.206.016 (+- 29%)
Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:
2.966.412.032 oder 1.622.000.000
Mitarbeiter
224 (+- 26%)
Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:
166 oder 281 Mitarbeiter
KGV
67.39
EBITDA 27.509.000
Buchwert 9.908
Die letzten Quartalsergebnisse Erwarteter Gewinn je Aktie beim aktuellen Wert von 30,22 EUR -1,01%
Portrait der Xencor Aktie
Das Unternehmen Xencor, Inc aus USA beschäftigt 224 Mitarbeiter und ist in den Bereichen Chemie & Pharma, Biotechnologie tätig.
Das Unternehmen Xencor, Inc ist nur in 7 ETFs enthalten und somit eine nicht sonderlich bekannte oder beliebte Aktie. Der Spitzenreiter iShares S&P SmallCap 600 UCITS ETF gewichtet Xencor mit 0,18% im ETF.
Entdecke die 6 ETFs in denen Xencor, Inc am höchsten gewichtet ist Insgesamt in 7 ETFs enthalten
Dir gefallen die Informationen zu Xencor?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne gerne ein kostenloses und unverbindliches Depot bei der ING Diba. Ich erhalte 20 wenn du daraufhin dann zum Beispiel einen Aktien-Sparplan anlegst oder etwas kaufst:
Zur ING Diba
Dir gefallen die Informationen zu Xencor?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne ein kostenloses und unverbindliches Depot bei BUX Zero mit der Möglichkeit kostenlos US-Aktien und für einen Euro viele weitere Aktien aus Deutschland, Belgien, Niederlande, sterreich oder UK zu kaufen. Wenn du das über meinen Link machst, bekommen wir beide eine gratis Aktie geschenkt:
Zu BUX Zero
Dir gefallen die Informationen zu Xencor?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein kostenloses und unverbindliches Depot bei Trade Republic mit der Möglichkeit kostenlos Aktien zu besparen. Wenn du das über meinen Link machst, bekommst du und ich bei deinem ersten Wertpapierkauf 15 von Trade Republic geschenkt:
Zu Trade Republic
Dir gefallen die Informationen zu Xencor?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein mindestens 3 Jahre lang kostenloses Depot bei der comdirect. Wenn du das über diesen Link machst unterstützt du auch meine Tochter Zoe, da es Ihr Juniordepot ist. Sie erhält 20 und bei einem aktiven ETF- oder Aktien-Sparplan bleibt dein Depot auch danach kostenfrei:
Zur Comdirect
24 News & Informationen zur Xencor Aktie
MorphoSys : The decision by the European Commission is based on data from the L-MIND study evaluating tafasitamab in combination with lenalidomide as a treatment for patients with relapsed or refracto
developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc., for the treatment of plaque psoriasis – became the first drug based on MorphoSys' antibody technology to receive… | August 27, 2021
The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Au…
MorphoSys : and Incyte Announce the European Commission Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory DLBCL
developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc., for the treatment of plaque psoriasis – became the first drug based on MorphoSys' antibody technology to… | August 26, 2021
Baker Bros. Advisors Lp Buys Verve Therapeutics Inc, Nurix Therapeutics Inc, Legend Biotech Corp, Sells , Invitae Corp, ChemoCentryx Inc
GuruFocus Article or News written by insider and the topic is about:
MorphoSys : Health Canada Grants Marketing Authorization for Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymp
developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc., for the treatment of plaque psoriasis – became the first drug based on MorphoSys' antibody technology to… | August 24, 2021
MorphoSys' : Partner Incyte Announced Development and Commercialization Agreement with InnoCare for Tafasitamab in Greater China (Form 6-K)
developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis – became the first drug based on MorphoSys' antibody technology to receive… | August 17, 2021
Incyte, InnoCare In Collaboration And License Deal For Tafasitamab In Greater China
(RTTNews) – Biopharmaceutical company Incyte Corp. (INCY) announced Tuesday that it has entered into a collaboration and license agreement with a …
PRESS RELEASE : MorphoSys' Partner Incyte Announced Development and Commercialization Agreement with InnoCare for Tafasitamab in Greater China
developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis – became the first drug based on MorphoSys' antibody technology to… | August 17, 2021
Incyte And InnoCare Announce Collaboration And License Agreement For Tafasitamab In Greater China
Incyte INCY and InnoCare (HKEX: 09969) today announced that Incyte and a subsidiary of InnoCare have entered into a collaboration and license agreement for the
Xencor, Inc. 2021 Q2 – Results – Earnings Call Presentation (NASDAQ:XNCR)
The following slide deck was published by Xencor, Inc.
Xencor, Inc. (XNCR) CEO Bassil Dahiyat on Q2 2021 Results – Earnings Call Transcript
Xencor, Inc. (NASDAQ:XNCR) Q2 2021 Earnings Conference Call August 4, 2021 16:30 ET Company Participants Charles Liles – Head, Corporate Communications and Investor Relations Bassil Dahiyat…
Xencor, inc (XNCR) Q2 2021 Earnings Call Transcript
XNCR earnings call for the period ending June 30, 2021.
12 Best Bear Market Stocks to Buy Now
The Centers for Disease Control and Prevention (CDC) in the United States on July 28 asked Americans who had been vaccinated against the coronavirus to start wearing masks in public indoor spaces again…
MorphoSys : Reports Second Quarter and First Half 2021 Results (Form 6-K)
developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis – became the first drug based on MorphoSys' antibody technology to receive… | July 29, 2021
Xencor (XNCR) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Xencor (XNCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
5 Mid-Cap Healthcare Stocks You'll Want on Your Radar for the 2nd Half of 2021
These biotech stocks could have great long-term potential.
Hedge Funds Are Selling Accolade, Inc. (ACCD)
Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 900…
LPC West : Acquires Pasadena Office Campus at 465 North Halstead; Xencor to Relocate Headquarters to the Property
Xencor will lease more than half of the space in the East Pasadena office campus; Relocation marks continued growth of the life sciences industry in Los Angeles …
Should I Avoid Jack in the Box Inc. (JACK)?
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data….
Xencor (XNCR) Loses 12.1% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Xencor (XNCR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Zacks Industry Outlook Highlights: Xencor, Organogenesis Holdings, Cumberland Pharmaceuticals and Acer Therapeutics
Zacks Industry Outlook Highlights: Xencor, Organogenesis Holdings, Cumberland Pharmaceuticals and Acer Therapeutics
Small Cap Stocks to Buy and Hold
There are numerous small cap stocks to buy and hold in your investment portfolio. This gives you a great chance to capitalize on each companies' potential.
Stocks That Hit 52-Week Highs On Friday
This morning 470 companies set new 52-week highs.
Facts of Interest: Tesla (NASDAQ:TSLA) was the largest firm on a market cap basis to set a …
The Daily Biotech Pulse: Sarepta Gene Therapy Study Readout, Novavax Vaccine Supply Deal, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Jan. 7) …